Asthma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Anti-inflammatory, Combination Therapy, Bronchodilators), By Product (Inhalers (Dry powder inhalers, Metered dose inhalers, Soft mist inhalers), Nebulizers), By Route of Administration (Oral, Inhaled, Others), By Region and Competition, 2020-2030F

November 2025 | 185 pages | ID: A11DDC5C9679EN
TechSci Research

Abstracts

The Global Asthma Therapeutics Market will grow from USD 27.52 Billion in 2024 to USD 34.3 Billion by 2030 at a 3.74% CAGR. Asthma therapeutics encompass a range of pharmaceutical medications and treatment modalities designed to manage and alleviate the symptoms of asthma, a chronic respiratory condition characterized by airway inflammation and narrowing. The market's growth is primarily driven by the escalating global prevalence of asthma, particularly in urbanized regions, and the increasing awareness regarding disease management.

Key Market Drivers

The increasing global asthma prevalence significantly propels the demand for therapeutics. A growing number of individuals worldwide are diagnosed with this chronic respiratory condition, necessitating long-term management and various treatment interventions. This expanding patient population inherently broadens the market for existing medications and drives the need for new therapeutic developments. Factors such as urbanization, increased exposure to environmental allergens, and lifestyle changes contribute to the rising incidence of asthma across diverse demographics.

Key Market Challenges

The high cost associated with advanced biologic therapies represents a significant challenging factor for the global asthma therapeutics market. This elevated pricing directly impacts patient access, particularly in diverse healthcare systems where reimbursement policies or individual financial capacities may be restrictive. Consequently, a substantial portion of the patient population requiring these advanced treatments may face barriers to obtaining them, thereby limiting the overall market penetration and expansion of these innovative therapies.

Key Market Trends

This trend transforms asthma management via real-time data and enhanced medication adherence. Digital health platforms and smart inhalers, with sensors, monitor usage and technique, directly improving treatment efficacy. Over 35 million people in the U.S. lived with a chronic lung condition in 2023, as reported by the American Lung Association in September 2024, highlighting the need for these solutions. Such integration enables personalized adjustments and better patient-provider communication. For example, Adherium announced in April 2024 that its Hailie Smartinhaler received FDA clearance for AstraZeneca’s Airsupra and Breztri inhalers, providing real-time medication usage insights. These advancements drive demand for technologically integrated therapeutics.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• GSK plc.
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca plc.
• Boehringer Ingelheim International GmbH
• Sanofi S.A.
• Koninklijke Philips N.V.
• Becton, Dickinson and Company
• Sunovion Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Asthma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Asthma Therapeutics Market, By Drug Class:
• Anti-inflammatory
• Combination Therapy
• Bronchodilators
• Asthma Therapeutics Market, By Product:
• Inhalers
• Nebulizers
• Asthma Therapeutics Market, By Route of Administration:
• Oral
• Inhaled
• Others
• Asthma Therapeutics Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Asthma Therapeutics Market.

Available Customizations:

Global Asthma Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL ASTHMA THERAPEUTICS MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Drug Class (Anti-inflammatory, Combination Therapy, Bronchodilators)
  5.2.2. By Product (Inhalers, Nebulizers)
  5.2.3. By Route of Administration (Oral, Inhaled, Others)
  5.2.4. By Region
  5.2.5. By Company (2024)
5.3. Market Map

6. NORTH AMERICA ASTHMA THERAPEUTICS MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Drug Class
  6.2.2. By Product
  6.2.3. By Route of Administration
  6.2.4. By Country
6.3. North America: Country Analysis
  6.3.1. United States Asthma Therapeutics Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Drug Class
      6.3.1.2.2. By Product
      6.3.1.2.3. By Route of Administration
  6.3.2. Canada Asthma Therapeutics Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Drug Class
      6.3.2.2.2. By Product
      6.3.2.2.3. By Route of Administration
  6.3.3. Mexico Asthma Therapeutics Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Drug Class
      6.3.3.2.2. By Product
      6.3.3.2.3. By Route of Administration

7. EUROPE ASTHMA THERAPEUTICS MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Drug Class
  7.2.2. By Product
  7.2.3. By Route of Administration
  7.2.4. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Asthma Therapeutics Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Drug Class
      7.3.1.2.2. By Product
      7.3.1.2.3. By Route of Administration
  7.3.2. France Asthma Therapeutics Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Drug Class
      7.3.2.2.2. By Product
      7.3.2.2.3. By Route of Administration
  7.3.3. United Kingdom Asthma Therapeutics Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Drug Class
      7.3.3.2.2. By Product
      7.3.3.2.3. By Route of Administration
  7.3.4. Italy Asthma Therapeutics Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Drug Class
      7.3.4.2.2. By Product
      7.3.4.2.3. By Route of Administration
  7.3.5. Spain Asthma Therapeutics Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Drug Class
      7.3.5.2.2. By Product
      7.3.5.2.3. By Route of Administration

8. ASIA PACIFIC ASTHMA THERAPEUTICS MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Drug Class
  8.2.2. By Product
  8.2.3. By Route of Administration
  8.2.4. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Asthma Therapeutics Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Drug Class
      8.3.1.2.2. By Product
      8.3.1.2.3. By Route of Administration
  8.3.2. India Asthma Therapeutics Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Drug Class
      8.3.2.2.2. By Product
      8.3.2.2.3. By Route of Administration
  8.3.3. Japan Asthma Therapeutics Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Drug Class
      8.3.3.2.2. By Product
      8.3.3.2.3. By Route of Administration
  8.3.4. South Korea Asthma Therapeutics Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Drug Class
      8.3.4.2.2. By Product
      8.3.4.2.3. By Route of Administration
  8.3.5. Australia Asthma Therapeutics Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Drug Class
      8.3.5.2.2. By Product
      8.3.5.2.3. By Route of Administration

9. MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Drug Class
  9.2.2. By Product
  9.2.3. By Route of Administration
  9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Asthma Therapeutics Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Drug Class
      9.3.1.2.2. By Product
      9.3.1.2.3. By Route of Administration
  9.3.2. UAE Asthma Therapeutics Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Drug Class
      9.3.2.2.2. By Product
      9.3.2.2.3. By Route of Administration
  9.3.3. South Africa Asthma Therapeutics Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Drug Class
      9.3.3.2.2. By Product
      9.3.3.2.3. By Route of Administration

10. SOUTH AMERICA ASTHMA THERAPEUTICS MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Drug Class
  10.2.2. By Product
  10.2.3. By Route of Administration
  10.2.4. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Asthma Therapeutics Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Drug Class
      10.3.1.2.2. By Product
      10.3.1.2.3. By Route of Administration
  10.3.2. Colombia Asthma Therapeutics Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Drug Class
      10.3.2.2.2. By Product
      10.3.2.2.3. By Route of Administration
  10.3.3. Argentina Asthma Therapeutics Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Drug Class
      10.3.3.2.2. By Product
      10.3.3.2.3. By Route of Administration

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL ASTHMA THERAPEUTICS MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Teva Pharmaceutical Industries Ltd.
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. GSK plc.
15.3. Merck & Co., Inc.
15.4. F. Hoffmann-La Roche Ltd.
15.5. AstraZeneca plc.
15.6. Boehringer Ingelheim International GmbH
15.7. Sanofi S.A.
15.8. Koninklijke Philips N.V.
15.9. Becton, Dickinson and Company
15.10. Sunovion Pharmaceuticals, Inc.

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER